Neurofibromatosis Type 2 - 25 Studies Found
Recruiting |
: Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors :
: 2016-10-13 : Drug: Icotinib Method of drug administration:oral; Dosage: 125mg/m3/d; Course of treatment: 3 months;Tot |
Completed |
: Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors :
: 2014-03-26 : Drug: Endostatin Method of drug administration:continuous intravenous pumping; Dosage: 7.5mg/m2/d; Cours |
Recruiting |
: Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas :
: 2014-04-29 : Drug: Axitinib Other Name: Inlyta |
Completed |
: Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2 : Neurofibromatosis Type II : 2011-08-17 : Drug: Everolimus (RAD001) , Afinitor® Everolimus will be provided by Novartis. Everolimus is formul |
Suspended |
: PTC299 for Treatment of Neurofibromatosis Type 2 : Neurofibromatosis 2 : 2009-05-28 : Drug: PTC299 PTC299 will be administered orally at 100 mg/dose twice per day for up to 1 year or until t |
Recruiting |
: Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma :
: 2011-04-21 : Drug: RAD001, everolimus Adults: 10 mg p.o. daily dose, age 16 - 17: 3.0 mg/m2 p.o. daily |
Completed |
: Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2) :
: 2010-09-01 :
|
Active, not recruiting |
: Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas :
: Drug: Bevacizumab Treatment will be administered on an out |
No longer available |
: Compassionate Use Arm - ABI541 ABI for 10 NF2 Patients :
|
Completed |
: Efficacy and Safety Study of RAD001 in the Growth of the Vestibular Schwannoma(s) in Neurofibromatosis 2 (NF2) Patients : Neurofibromatosis 2 : 2011-11-30 : Drug: RAD001 10 mg per os / day or 05mg per os / day with 12 month |